The HCC surveillance programs that could lead to early cancer detection and effective treatment are based on heterogeneous scoring systems that require costly measures. Our study revealed that it is of clinical benefit to identify genetic traits as EGF +61 A/G polymorphism, that can modify liver carcinogenesis, and potentially be used to improve preventive and therapeutic strategies in HCC management.